ALTANA advised BIOALLIANCE PHARMA in its cross-border corporate merger with TOPOTARGET, a Danish biotech company, to create a leader in orphan oncology disease treatments. Each of the two companies have more than 8,000 shareholders and the market capitalization of the combined entity will exceed €200 million. This merger is the first-ever cross border merger of a French listed company with a listed company of a different nationality under the 2005 merger Directive.